- Tariquidar
-
- $45.00 / 5mg
-
2024-11-19
- CAS:206873-63-4
- Min. Order:
- Purity: 99.17%
- Supply Ability: 10g
- Tariquidar
-
- $0.00 / 1KG
-
2022-10-14
- CAS:206873-63-4
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
- Tariquidar
-
- $15.00 / 1KG
-
2021-07-13
- CAS:206873-63-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Tariquidar Basic information |
| Product Name: | Tariquidar | | Synonyms: | N-[2-[[[4-[2-(3,4-Dihydro-6,7-diMethoxy-isoquinolin-2(1H)-yl)ethyl]phenyl]aMino]carbonyl]-4,5-diMethoxyphenyl]-3-quinolinecarboxaMide;N-[2-({4-[2-(6,7-diMethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbaMoyl)-4,5-diMethoxyphenyl]quinoline-3-carboxaMide;N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide Tariquidar;Tariquidar
N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide;Tariquidar, >=98%;XL9576 Free base;N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxy-phenyl]quinoline-3-carboxamide;Tariquidar | | CAS: | 206873-63-4 | | MF: | C38H38N4O6 | | MW: | 646.73 | | EINECS: | | | Product Categories: | Inhibitors;Anti-cancer&immunity;Inhibitor | | Mol File: | 206873-63-4.mol |  |
| | Tariquidar Chemical Properties |
| Melting point | >190oC (dec.) | | Boiling point | 716.0±60.0 °C(Predicted) | | density | 1.276±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 10.67±0.70(Predicted) | | form | powder | | color | white to light brown |
| | Tariquidar Usage And Synthesis |
| Description | Tariquidar is an anthranilic acid derivative that binds to P-glycoprotein (Kd = 5.1 nM) and inhibits transport activity. It inhibits transport of vinblastine and paclitaxel in multidrug resistant CHrB30 cells, increasing the steady state accumulation to non-P-glycoprotein-expressing multidrug sensitive cell levels (EC50 = 487 nM). Tariquidar also enhances the distribution of its substrates, increasing the amount of substrate entering the CNS. When administered at doses of 2 and 6.25 mg/kg in mice in combination with the peripherally-restricted opioid loperamide, the latency to paw withdrawal in a hot plate assay increases, indicating that loperamide is transported into the CNS. | | Uses | Tariquidar is a p-glycoprotein drug efflux pump inhibitor. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both.Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer. | | Definition | ChEBI: Tariquidar is a member of benzamides. | | Biochem/physiol Actions | Specific inhibitor of MDR-1 (P-gp) | | target | P-glycoprotein |
| | Tariquidar Preparation Products And Raw materials |
|